Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sickle cell drug pociredir tested for Long-Term safety in extended study

NCT ID NCT07401823

First seen Feb 12, 2026 · Last updated May 23, 2026 · Updated 18 times

Summary

This study looks at the long-term safety of a daily pill called pociredir for adults with sickle cell disease who have already taken it and seen benefits in a previous study. About 50 participants will take the drug once a day for up to 48 months. Researchers will monitor side effects and changes in blood tests to see if the drug remains safe over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Boston Medical Center

    Boston, Massachusetts, 02118, United States

  • Inova Schar Cancer Institute

    Fairfax, Virginia, 22031, United States

  • Jacobi Medical Center

    The Bronx, New York, 10461, United States

  • Our Lady of the Lake Hospital

    Baton Rouge, Louisiana, 70808, United States

  • Queens Hospital Cancer Center

    Jamaica, New York, 11432, United States

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas, 72205, United States

  • University of California, Los Angeles

    Los Angeles, California, 90095, United States

  • University of Texas Houston

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.